JP2001522232A - 望ましくない細胞を排除するための組成物および方法 - Google Patents
望ましくない細胞を排除するための組成物および方法Info
- Publication number
- JP2001522232A JP2001522232A JP53934998A JP53934998A JP2001522232A JP 2001522232 A JP2001522232 A JP 2001522232A JP 53934998 A JP53934998 A JP 53934998A JP 53934998 A JP53934998 A JP 53934998A JP 2001522232 A JP2001522232 A JP 2001522232A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- vector
- cell
- syncytium
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.悪性疾患の遺伝子治療において使用するための組換え核酸ベクターであって 、該ベクターはシンシチウム誘導性ポリペプチドの真核細胞表面での発現を誘導 する、ベクター。 2.該ベクターは、ウイルス融合誘導性膜糖タンパク質(FMG)の少なくとも 融合誘導性部分の発現を誘導する、請求項1に記載のベクター。 3.該ベクターは、天然に存在しないポリペプチドの発現を誘導する、請求項1 または2に記載のベクター。 4.キメラポリペプチドの発現を誘導する、請求項1、2または3のいずれかに 記載のベクター。 5.人工的に導入されたプロテアーゼに対する感受性または結合特異性、または 強化された融合誘導性を有する、融合誘導性膜糖タンパク質の発現を誘導する、 請求項1〜4のいずれか1項に記載のベクター。 6.請求項1〜5のいずれか1項に記載のベクターを含む宿主細胞。 7.請求項6に記載のヒト宿主細胞。 8.腫瘍性細胞、移動性細胞、Tリンパ球、Bリンパ球または他の造血細胞から なる群より選択される、請求項6または7に記載の宿主細胞。 9.ヒトの患者の悪性疾患を治療するための方法であって、該患者に対して、請 求項1〜5のいずれか1項に記載の組換え核酸ベクター、または請求項6〜8の いずれか1項に記載の複数の宿主細胞を投与することによって、悪性疾患を引起 している癌性細胞の細胞融合を引起すことを含む、方法。 10.ヒトの患者の悪性疾患の治療における、請求項1〜5のいずれか1項に記 載のベクターの使用、または、請求項6〜8のいずれか1項に記載の複数の宿主 細胞の使用。 11.ヒトの患者の悪性疾患を治療するための医薬の調製における、請求項1〜 5のいずれか1項に記載の組換え核酸ベクターの使用、または、請求項6〜8の いずれか1項に記載の複数の宿主細胞の使用。 12.医薬として許容される担体との混合物において、請求項1〜5のいずれか 1項に記載のベクターまたは請求項6〜8のいずれか1項に記載の複数の宿主細 胞を含む、医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9705007.4A GB9705007D0 (en) | 1997-03-11 | 1997-03-11 | Improvements in or relating to therapeutic genes |
US4516497P | 1997-04-30 | 1997-04-30 | |
US9705007.4 | 1997-04-30 | ||
US60/045,164 | 1997-04-30 | ||
PCT/GB1998/000710 WO1998040492A1 (en) | 1997-03-11 | 1998-03-10 | Compositions and methods for elimination of unwanted cells |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001522232A true JP2001522232A (ja) | 2001-11-13 |
JP2001522232A5 JP2001522232A5 (ja) | 2005-11-10 |
JP4422804B2 JP4422804B2 (ja) | 2010-02-24 |
Family
ID=26311163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53934998A Expired - Lifetime JP4422804B2 (ja) | 1997-03-11 | 1998-03-10 | 望ましくない細胞を排除するための組成物および方法 |
Country Status (8)
Country | Link |
---|---|
US (7) | US6750206B2 (ja) |
EP (1) | EP0966534B1 (ja) |
JP (1) | JP4422804B2 (ja) |
AT (1) | ATE288488T1 (ja) |
AU (1) | AU744882B2 (ja) |
CA (1) | CA2283536C (ja) |
DE (1) | DE69828874T2 (ja) |
WO (1) | WO1998040492A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE288488T1 (de) * | 1997-03-11 | 2005-02-15 | Mayo Foundation | Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen |
FR2786773B1 (fr) * | 1998-12-03 | 2002-03-08 | Univ Paris Curie | Proteines d'enveloppe, methodes et utilisations |
WO2000071578A2 (en) * | 1999-05-20 | 2000-11-30 | Cnrs Centre National De La Recherche Scientifique | New polypeptides and their use for the rescue of fusion defective virus or retrovirus glycoproteins |
GB9925966D0 (en) * | 1999-11-02 | 1999-12-29 | Petrik Juraj | Threapeutic vaccines against variable viruses and other targets |
AU2001251138A1 (en) * | 2000-03-31 | 2001-10-15 | Mayo Foundation For Medical Education And Research | Compositions and methods for tissue specific gene regulation therapy |
WO2002080983A1 (en) * | 2001-04-05 | 2002-10-17 | The Uab Research Foundation | Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins |
US20040265805A1 (en) * | 2002-05-02 | 2004-12-30 | Monsanto Technology, L.L.C. | Method for cloning large DNA |
GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
US9241998B2 (en) * | 2007-05-21 | 2016-01-26 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oncolytic RSV activity |
WO2017201281A1 (en) | 2016-05-18 | 2017-11-23 | Mayo Foundation For Medical Education And Research | Targeting pd-l1 on tumor cells |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE183235T1 (de) * | 1990-03-21 | 1999-08-15 | Wolf Hans Joachim Prof Dr | Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon |
US5847096A (en) * | 1991-08-30 | 1998-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA constructs encoding CD4 fusion proteins |
US5420011A (en) * | 1993-04-12 | 1995-05-30 | The United States Of America As Represented By The Department Of Health And Human Services | Cell bioassay for neurotoxins |
GB9308963D0 (en) | 1993-04-30 | 1993-06-16 | Smithkline Beecham Biolog | Novel compounds |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5753499A (en) * | 1994-12-23 | 1998-05-19 | New York University | Viral vector complexes having adapters of predefined valence |
DE69634750T2 (de) | 1995-03-31 | 2006-02-23 | Université Libre de Bruxelles | DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT |
US5674734A (en) | 1995-05-18 | 1997-10-07 | President And Fellows Of Harvard College | Cell death protein |
GB9514368D0 (en) | 1995-07-13 | 1995-09-13 | Medical Res Council | Improvements in or relating to binding assays |
US5869036A (en) * | 1995-12-08 | 1999-02-09 | St. Louis University | Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine |
DE19605279A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
ATE288488T1 (de) * | 1997-03-11 | 2005-02-15 | Mayo Foundation | Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen |
US5882893A (en) * | 1997-12-04 | 1999-03-16 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding muscarinic receptors and uses therefor |
-
1998
- 1998-03-10 AT AT98909593T patent/ATE288488T1/de not_active IP Right Cessation
- 1998-03-10 EP EP98909593A patent/EP0966534B1/en not_active Expired - Lifetime
- 1998-03-10 JP JP53934998A patent/JP4422804B2/ja not_active Expired - Lifetime
- 1998-03-10 AU AU64084/98A patent/AU744882B2/en not_active Ceased
- 1998-03-10 CA CA002283536A patent/CA2283536C/en not_active Expired - Fee Related
- 1998-03-10 WO PCT/GB1998/000710 patent/WO1998040492A1/en active IP Right Grant
- 1998-03-10 DE DE69828874T patent/DE69828874T2/de not_active Expired - Lifetime
- 1998-04-30 US US09/070,630 patent/US6750206B2/en not_active Expired - Fee Related
-
2003
- 2003-12-10 US US10/732,438 patent/US7314868B2/en not_active Expired - Fee Related
-
2005
- 2005-08-18 US US11/206,416 patent/US7317004B2/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/932,400 patent/US20080227740A1/en not_active Abandoned
- 2007-10-31 US US11/932,092 patent/US20080226610A1/en not_active Abandoned
- 2007-10-31 US US11/932,089 patent/US7846429B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,193 patent/US20080171027A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4422804B2 (ja) | 2010-02-24 |
US7314868B2 (en) | 2008-01-01 |
AU6408498A (en) | 1998-09-29 |
US20030095947A1 (en) | 2003-05-22 |
CA2283536A1 (en) | 1998-09-17 |
EP0966534A1 (en) | 1999-12-29 |
US20080171026A1 (en) | 2008-07-17 |
DE69828874D1 (de) | 2005-03-10 |
WO1998040492A1 (en) | 1998-09-17 |
AU744882B2 (en) | 2002-03-07 |
US20080226610A1 (en) | 2008-09-18 |
US7846429B2 (en) | 2010-12-07 |
US20080171027A1 (en) | 2008-07-17 |
EP0966534B1 (en) | 2005-02-02 |
CA2283536C (en) | 2009-09-01 |
US20060051335A1 (en) | 2006-03-09 |
DE69828874T2 (de) | 2005-07-07 |
ATE288488T1 (de) | 2005-02-15 |
US6750206B2 (en) | 2004-06-15 |
US20080227740A1 (en) | 2008-09-18 |
US7317004B2 (en) | 2008-01-08 |
US20040253214A1 (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7846429B2 (en) | Compositions and methods for elimination of unwanted cells | |
Blömer et al. | Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector | |
US7179903B2 (en) | Liver specific transcriptional enhancer | |
EP0795021B1 (en) | Retroviral delivery of full length factor viii | |
US7820157B2 (en) | Transgene delivering retrovirus targeting collagen exposed at site of tissue injury | |
Shichinohe et al. | Development of lentiviral vectors for antiangiogenic gene delivery | |
CA2920049A1 (en) | Recombinant vector with optimized a-bulge | |
US20030119770A1 (en) | Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors | |
Lyerly et al. | Gene delivery systems in surgery | |
US20050112098A1 (en) | Pseudotyped viruses and methods for their use | |
EP1264892A2 (en) | Lentiviral vectors comprising endothelial cell specific promoters | |
Gordon et al. | Genetic engineering of targeted retroviral vectors | |
Jimenez | Gene therapy for malignant brain tumors | |
Chai | Identification of a receptor for an avian retrovirus and characterization of a novel gene delivery vector | |
CA2234219A1 (en) | Retroviral vectors pseudotyped with srv-3 envelope glycoprotein sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050224 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071127 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091110 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091207 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121211 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131211 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |